Tarsier Pharma Series B

Tarsier Pharma is a late clinical-stage company developing bio-inspired medical solutions for autoimmune and inflammatory ocular diseases. Their breakthrough platform technology, Dazdotuftide (TRS), aims to re-engineer the immune system to treat conditions like uveitis, with a pipeline including eye drops and intravitreal injections. They serve patients suffering from blinding ocular diseases and provide information for healthcare providers and investors.